page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Medroxyprogesterone (Provera, Cycrin, Depo-Provera)

Category:

  • Hormonal

Description:

  • Progesterone hormone

Indications:

  • Abnormal uterine bleeding (due to hormonal imbalance in the absence of organic pathology)

  • Secondary amenorrhea

  • Contraception

Contraindications:

  • Current or history of thrombophlebitis, thromboembolic disorders, and cerebral apoplexy

  • Liver impairment, known or suspected malignancy of the breast or genitalia

  • Undiagnosed genital bleeding

  • Missed abortion

  • Use as a pregnancy diagnostic test

Precautions:

  • Pregnancy category D (Provera and Cycrin)

  • Pregnancy category X (Depo Provera)

  • Use with caution in pregnant or nursing mothers

  • Use with caution in patients with diabetes, epilepsy, migraine, asthma, cardiac or renal dysfunction, or history of depression.

  • Injectable form of contraception has an extended duration of three months.

  • Immediately discontinue therapy and consult health care provider if pregnancy is suspected.

Adverse Reactions (Side Effects):

  • Rash, alopecia, acne, hirsutism

  • Abnormal menstrual bleeding, changes in cervical secretions

  • Edema, weight change

  • Depression, insomnia, somnolence

  • Nausea

  • Injection site irritation

Dosage:

Administered orally or injection

  • Abnormal uterine bleeding: 

    • 5-10mg daily for 5-10 days initiated on 16th or 21st day of cycle

  • Secondary amenorrhea: 

    • 5-10mg daily for 5-10 days

  • Contraception: 

    • 150mg IM injection (gluteal or deltoid muscle) every three months, given in first 5 days of normal menstrual cycle

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site